Autopsy report · NCT00612898
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 239 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Avexa
- Sponsor type
- Industry
- Conditions
- HIV Infections
- Interventions
- apricitabine; lamivudine
- Participants
- 239
- Sites
- 100
- Countries
- Australia, Belgium, Canada, Germany, Israel, Italy, Peru, Puerto Rico, Thailand, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.